• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芬氟拉明对肥胖受试者的长期治疗。

Long-term treatment with fenfluramine in obese subjects.

作者信息

Sensi S, Della Loggia F, Del Ponte A, Guagnano M T

出版信息

Int J Clin Pharmacol Res. 1985;5(4):247-53.

PMID:4055167
Abstract

The effect of fenfluramine, an anorectical drug, given for nine months to a group of 156 obese subjects, on body-weight and adipose mass reduction as well as on glucose tolerance, has been studied. Subjects were divided in four different groups according to various protocols of therapy: the first group took the drug once a day in a single 60 mg dose in the morning; the second group received the drug once a day in a single 40 mg dose in the morning; the third group took the drug divided in three equal daily doses and the last group was treated with diet alone. During the first three months of treatment, fenfluramine 60 mg, given both in a single dose in the morning and divided in three equal daily doses, combined with diet, produces a significant body-weight reduction in comparison with the group of obese subjects treated with diet alone. In the following three months, it was possible to document a further body weight loss in all subjects, whatever the group to which they were assigned. At the end of the sixth month of observation, only slight differences could be demonstrated among the groups as regards the body-weight and adipose mass decrease. In addition the results failed to demonstrate a statistically different weight loss when the drug as administered in a single dose in the morning, compared with the conventional treatment of three times a day. No significant improvement of glucose tolerance was documented. In conclusion, in long-term treatment with fenfluramine, in contrast with short-term studies, no direct effect of this drug on body-weight and adipose mass decrease was demonstrated.

摘要

研究了食欲抑制药芬氟拉明对156名肥胖受试者连续九个月的给药效果,包括对体重和脂肪量减少以及葡萄糖耐量的影响。根据不同的治疗方案,受试者被分为四组:第一组每天早晨单次服用60毫克药物;第二组每天早晨单次服用40毫克药物;第三组将药物分成三个相等的日剂量服用,最后一组仅接受饮食治疗。在治疗的前三个月,早晨单次服用60毫克芬氟拉明以及将其分成三个相等的日剂量并结合饮食,与仅接受饮食治疗的肥胖受试者组相比,能显著减轻体重。在接下来的三个月里,无论受试者被分配到哪一组,都能观察到体重进一步下降。在观察的第六个月末,各组在体重和脂肪量减少方面仅显示出微小差异。此外,与每日三次的常规给药相比,早晨单次给药时,结果未能显示出统计学上不同的体重减轻情况。未记录到葡萄糖耐量的显著改善。总之,与短期研究相比,在芬氟拉明的长期治疗中,未证明该药物对体重和脂肪量减少有直接作用。

相似文献

1
Long-term treatment with fenfluramine in obese subjects.芬氟拉明对肥胖受试者的长期治疗。
Int J Clin Pharmacol Res. 1985;5(4):247-53.
2
[Chronotherapy of obesity. I. Effect of fenfluramine on the decrease of adipose mass in the obese, in relation to the time of administration].[肥胖症的时间治疗法。I. 氟苯丙胺对肥胖者脂肪量减少的影响与给药时间的关系]
Boll Soc Ital Biol Sper. 1982 Jun 30;58(12):736-9.
3
[Is it possible to obtain a reduction of body weight exclusively via a loss in fat mass? Experience with d-fenfluramine].[仅通过减少脂肪量就能减轻体重吗?右旋芬氟拉明的经验]
Recenti Prog Med. 1993 Feb;84(2):100-5.
4
[Activity of fenfluramine in obese subjects. Relation between dosage, plasma concentration of the drug and its effect on weight loss].[芬氟拉明在肥胖受试者中的活性。药物剂量、血浆浓度与其对体重减轻的影响之间的关系]
Minerva Med. 1982 Jun 8;73(24):1703-10.
5
[Chronotherapy of obesity. II. Variations in eating behavior in the obese after fenfluramine treatment in relation to time of administration].[肥胖症的时间疗法。II. 氟苯丙胺治疗后肥胖者饮食行为随给药时间的变化]
Boll Soc Ital Biol Sper. 1982 Jun 30;58(12):740-4.
6
X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.X-PERT研究:接受轻度或中度能量减少饮食的肥胖受试者使用奥利司他减重:治疗早期反应可预测体重维持情况
Diabetes Obes Metab. 2005 Nov;7(6):699-708. doi: 10.1111/j.1463-1326.2005.00483.x.
7
The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.1年西布曲明治疗对肥胖受试者糖耐量、胰岛素敏感性及血脂谱的影响。
Diabetes Nutr Metab. 2004 Apr;17(2):103-7.
8
[Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].右芬氟拉明对肥胖患者饮食行为和体重的影响:奥地利全科医疗中异芬氟拉明的一项现场研究结果
Acta Med Austriaca. 1995;22(5):95-101; 104-9.
9
[Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].[右芬氟拉明在私人诊所长期治疗肥胖症中的耐受性和可接受性。ESIM 集团]
Rev Med Suisse Romande. 1997 Jan;117(1):19-24.
10
A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.一项关于体重控制的双盲临床试验。单独及联合使用芬氟拉明和苯丁胺。
Arch Intern Med. 1984 Jun;144(6):1143-8.